Money flow gives a snapshot of relative buying and selling pressure in a stock. A ratio above one suggests greater buying pressure, below one suggests greater selling.
| Company | Change | P/E (TTM) |
|---|---|---|
VVUSVIVUS Inc. | +0.88% | - |
PRXLPAREXEL International Corp. | +1.39% | 23.95 |
WBMDWebMD Health Corp. | +0.40% | 29.76 |
PFEPfizer Inc. | +1.65% | 29.97 |
SMMESmartMetric Inc. | +13.33% | - |
QQuintiles Transnational Holdings Inc. | +2.53% | 24.34 |
VEEVVeeva Systems Inc. Cl A | -0.31% | 109.82 |
TNETTriNet Group Inc. | +2.95% | 37.95 |
TBIOTransgenomic Inc. | -2.76% | - |
Interpace Diagnostics Group, Inc. engages in the development and commercialization molecular diagnostic tests principally focused on early detection of high potential progressors to cancer. It offers commercialized molecular tests which include PancraGen, ThyGenX, and...
| Q3 2016 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Q4 2016 Estimate Trends | |
|---|---|
| Current: | $- |
| 1 month ago: | $- |
| 3 months ago: | $- |
| Jun 2016 | 5-quarter trend | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income Growth | +47.68% | | ||||||||||
| Sales or Revenue | 3.61 M | | ||||||||||
| Sales or Revenue Growth | -90.06% | | ||||||||||
| EBITDA | -1.76 M | | ||||||||||
| 2015 | 5-year trend | |||||||||||
| Net Income Growth | -230.46% | | ||||||||||
| Sales or Revenue | 9.43 M | | ||||||||||
| Sales or Revenue Growth | -92.14% | | ||||||||||
| EBITDA | -23.93 M | |